Hahn S S, Spaulding C A, Kim J A, Constable W C
Int J Radiat Oncol Biol Phys. 1987 Aug;13(8):1143-7. doi: 10.1016/0360-3016(87)90186-6.
Three hundred and thirty-three patients with carcinoma of the pyriform sinus or supraglottis were reviewed with regard to lymph node involvement and prognosis. All patients were treated with curative intent and had a minimum follow-up of 3 years. Every patient was restaged according to the AJCC, 1983 recommendations. In addition, nodal fixation to cervical fascia or muscle was evaluated with regard to prognosis. Seventy-five percent (89/119) of the pyriform sinus cancer and 47% (101/214) of the supraglottic cancer patients presented with clinically palpable cervical nodes. The distribution of patients according to N stage was 143 (43%), 84 (25%), 58 (17%), 48 (14%) for N0, N1, N2, N3 respectively. In patients where information on nodal fixation was available, 29% had fixed nodes. No difference in prognosis was noted between N0 and N1 or N2 and N3 stages, and these groups were therefore combined. The 3-year survival was 85% for T1 (N0/N1), 77% for T2 (N0/N1), 63% for T3 (N0/N1), and 65% for T4 (N0/N1) cases compared to 19% for T1 (N2/N3), 34% for T2 (N2/N3), 33% for T3 (N2/N3), and 32% for T4 (N2/N3) cases demonstrating that N stage predominates over T stage with respect to survival. Both the local recurrences and distant metastases increased as N stage advanced. A noteworthy difference between patients with fixed nodes and mobile nodes was found with regard to neck recurrence (35% versus 17%), distant metastases (33% versus 19%) and survival (27% versus 58%). In conclusion, nodal stage is a highly significant determinant of survival independent of T stage in cancers of the pyriform sinus and supraglottis. N0, N1 status and mobility were predictive of a favorable prognosis as opposed to N2, N3 status and fixation. These findings were consistent when the pyriform sinus cancers and supraglottic cancers were analyzed separately.
对333例梨状窦或声门上区癌患者的淋巴结受累情况及预后进行了回顾性研究。所有患者均接受了根治性治疗,且至少随访3年。每位患者均根据美国癌症联合委员会(AJCC)1983年的建议重新分期。此外,还评估了淋巴结与颈部筋膜或肌肉的固定情况对预后的影响。梨状窦癌患者中有75%(89/119)、声门上区癌患者中有47%(101/214)出现临床可触及的颈部淋巴结。根据N分期,患者分布情况分别为N0期143例(43%)、N1期84例(25%)、N2期58例(17%)、N3期48例(14%)。在有淋巴结固定信息的患者中,29%有固定淋巴结。N0与N1期或N2与N3期之间未观察到预后差异,因此将这些组合并。T1(N0/N1)期患者的3年生存率为85%,T2(N0/N1)期为77%,T3(N0/N1)期为63%,T4(N0/N1)期为65%;而T1(N2/N3)期为19%,T2(N2/N3)期为34%,T3(N2/N3)期为33%,T4(N2/N3)期为32%,这表明在生存率方面,N分期比T分期更具主导性。随着N分期的进展,局部复发和远处转移均增加。在颈部复发(35%对17%)、远处转移(33%对19%)和生存率(27%对58%)方面,发现固定淋巴结患者与活动淋巴结患者之间存在显著差异。总之,在梨状窦癌和声门上区癌中,淋巴结分期是独立于T分期的生存高度重要决定因素。与N2、N3状态及固定情况相反,N0、N1状态及活动情况预示着良好预后。分别分析梨状窦癌和声门上区癌时,这些结果是一致的。